Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites And Peripheral Edema In Patients With Cirrhosis And Diabetes

SGLT2-I (empagliflozin, canagliflozin and dapagliflozin) are the most recently approved drugs for type 2 diabetes (TD2) T2D is common in patients with cirrhosis, particularly in those with non-alcoholic steatohepatitis (NASH). SGLT2-I appear to be safe and well-tolerated in cirrhosis and because, besides promoting urinary glucose excretion, they also promote sodium excretion, they could have an additional benefit in those with ascites.